Page last updated: 2024-10-24

carteolol and Obesity

carteolol has been researched along with Obesity in 1 studies

Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Takahashi, H1
Nakano, K1
Yasuda, T1
Komiyama, Y1
Murakami, T1
Nishimura, M1
Nakanishi, T1
Sakamoto, M1
Nanbu, A1
Yoshimura, M1

Other Studies

1 other study available for carteolol and Obesity

ArticleYear
Anti-obesity and anti-diabetic effects of carteolol in non-insulin-dependent diabetic mice.
    Clinical and experimental pharmacology & physiology, 1994, Volume: 21, Issue:6

    Topics: Adipose Tissue, Brown; Animals; Blood Pressure; Body Weight; Carbohydrate Metabolism; Cardiac Output

1994